首页> 外文OA文献 >PCN101 A Cost-Effectiveness Analysis of Cisplatin Plus Pemetrexed Doublet Induction Treatment Followed by Pemetrexed Maintenance Compared with Bevacizumab Plus Cisplatin Plus Gemcitabine Triplet Induction Treatment Followed by Bevacizumab Maintenance for Non-Squamous NSCLC in Sweden

【2h】

PCN101 A Cost-Effectiveness Analysis of Cisplatin Plus Pemetrexed Doublet Induction Treatment Followed by Pemetrexed Maintenance Compared with Bevacizumab Plus Cisplatin Plus Gemcitabine Triplet Induction Treatment Followed by Bevacizumab Maintenance for Non-Squamous NSCLC in Sweden

机译：PCN101对瑞典非鳞状NSCLC进行顺铂加培美曲塞双线诱导治疗后培美曲塞维持治疗与贝伐单抗加顺铂加吉西他滨三线诱导治疗后贝伐单抗维持治疗的成本-效果分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Bryden P.A.; Kumar G.; Winfree K.B.; Boye M.E.; Taipale K.; Thompson R.; Borgeke H.;
展开▼
作者单位

展开▼
年度 2013
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Induction pemetrexed and cisplatin followed by maintenance pemetrexed versus carboplatin plus paclitaxel plus bevacizumab followed by maintenance bevacizumab: a quality of life-oriented randomized phase III study in patients with advanced non-squamous non-small-cell lung cancer (ERACLE). [J] . Galetta D, Pisconti S, Cinieri S, Clinical lung cancer . 2011,第6期

机译：培美曲塞和顺铂的诱导治疗，培美曲塞与卡铂+紫杉醇+贝伐单抗的维持治疗，贝伐珠单抗的维持治疗：针对晚期非鳞状非小细胞肺癌（ERACLE）患者的以生活为导向的随机III期临床研究。
2. Bevacizumab combined with pemetrexed plus cisplatin followed by maintenance bevacizumab/pemetrexed as first-line treatment of advanced non-squamous non-small cell lung cancer: A single-arm Phase 2 study [J] . SantoroA., HillerdalG.N., HoeffkenG., Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2014,第1期

机译：贝伐单抗联合培美曲塞加顺铂，然后维持贝伐单抗/培美曲塞作为一线治疗晚期非鳞状非小细胞肺癌的单臂2期研究
3. Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study [J] . Nishimoto Koji, Karayama Masato, Inui Naoki, Medical oncology . 2018,第7期

机译：用Cisplatin，Pemetrexed和Bevacizumab在先进的非鳞状非小细胞肺癌中进行切换维护治疗和Bevacizumab：II期研究
4. Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study [O] . Isabelle Borget, Maurice Pérol, David Pérol, 2014

机译：吉西他滨或厄洛替尼维持疗法与顺铂-吉西他滨诱导化疗后晚期NSCLC的预定义二线治疗观察相比的成本-效用分析：IFCT-GFPC 0502-Eco III期研究
5. PCN30 THE COSTS OF TREATING PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL CANCER (NSCLC) WITH BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE COMPARED WITH PEMETREXED PLUS CISPLATIN IN INDUCTION AND MAINTENANCE THERAPY IN GERMANY AND ITALY [O] . Nuijten M 2009

机译：PCN30在德国和意大利的诱导和维持治疗中，使用贝伐单抗加西帕汀和吉西他滨与培美曲塞加西普拉汀相比较的晚期或复发性非小细胞癌（NSCLC）患者的治疗成本

PCN101 A Cost-Effectiveness Analysis of Cisplatin Plus Pemetrexed Doublet Induction Treatment Followed by Pemetrexed Maintenance Compared with Bevacizumab Plus Cisplatin Plus Gemcitabine Triplet Induction Treatment Followed by Bevacizumab Maintenance for Non-Squamous NSCLC in Sweden

著录项

相似文献

相关主题

期刊订阅